Selection of biomarkers, such as Ki67, to stratify patients into clinically distinctive groups in a move towards personalised therapy will aid to improve poor responsiveness to anti-oestrogen therapies in patients with ER+/HER2+ tumours. This evidence concerns the gene ERBB2 and neoplasm.